Dermatology
Latest News
FDA panels vote to modify isotretinoin iPLEDGE REMS
The committees sought to balance reducing burden with maintaining safety and preventing fetal exposures to isotretinoin.
Latest News
Limited treatment options exist for brittle nail syndrome
“It’s our duty to warn our patients about the evidence for biotin for treating brittle nails, and about this interference on laboratory tests,” Dr...
Latest News
FDA Advisory panels consider easing isotretinoin requirements
The 2-day meeting is addressing what can be done to reduce burden with the iPLEDGE REMS while maintaining safety and preventing fetal exposure to...
Latest News
JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial
The co-primary endpoints were change in IGA and EASI scores at 16 weeks, and both improved rapidly, showing statistical significance relative to...
Latest News
Topical delgocitinib shows promise for chronic hand eczema, pivotal trial shows
Delgocitinib is an investigational topical pan-JAK inhibitor that inhibits activation of the JAK-STAT pathway.
Latest News
Air pollution may be causing eczema
There are now more than three times as many eczema cases as there were in the 1970s, and it now affects as many as 20% of children and 10% of...
News
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Latest News
Anifrolumab shows promise in refractory discoid lupus erythematosus
Anifrolumab improved symptoms and activity of DLE within 2 months in a study of eight women.
Latest News
New data forecast more oral PDE4 inhibitors for psoriasis
The phase 2b data suggest that the drug, called orismilast, “is a potential new addition to the psoriasis armamentarium,” said Lars E. French, MD...
Conference Coverage
New JAK inhibitor study data confirm benefit in alopecia areata
Deuruxolitinib (CTP-543), an inhibitor of the JAK1 and JAK2 enzymes, has the potential to become the second JAK inhibitor available for the...